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cells/L) and a C-reactive protein level of 406 mg/L; renal and liver profi les were normal. Results of a hemoglobin A1c blood test for diabetes were 13%, which is consistent with poorly controlled diabetes, and results of an HIV test and malaria screen were both negative. Ultrasonography of the swollen area showed localized, superfi cial, enlarged lymph nodes, posterior and inferior to the right pinna. Blood was drawn for culturing, and a course of intravenous fl ucloxacillin treatment was begun. Subsequently, the aerobic bottles of 2 sets of blood cultures were positive for gram-negative bacilli, and subculturing yielded an oxidasepositive, gram-negative bacillus that grew rapidly on blood agar as a gray colony with a metallic sheen. The organism was subsequently identifi ed as Burkholderia pseudomallei (see characterization of blood culture isolate). The antimicrobial drug therapy was changed to intravenous co-amoxiclav (1.2 g 3×/d), and 3 days later, when the identifi cation of the organism was confi rmed, the patient's treatment was switched to intravenous meropenem (2 g 3×/d). Results of a computed tomography scan of the chest and abdomen were normal. The patient's fever and lymphadenopathy subsequently resolved, and after 9 days of receiving meropenem, she was discharged with a 12-week course of oral co-trimoxazole (1,920 mg daily). The patient did not attend her scheduled outpatient appointment.
Two microbiology laboratory workers were judged to have had low-risk exposure to the organism before its identifi cation (1). They were counseled, and both chose not to receive antimicrobial drug prophylaxis. Serologic follow-up at 2 and 6 weeks postexposure for 1 worker showed no evidence of seroconversion to B. pseudomallei. The other did not attend her scheduled occupational health outpatient appointment.
Because the isolate could not be defi nitively identifi ed by using API20NE (bioMérieux, Marcy l'Etoile, France), it was sent to the UK Health Protection Agency reference laboratory for further analysis. The appearance of the organism in colonies on Ashdown agar was typical of B. pseudomallei. Moreover, the same identifi cation was reached through fatty acid methyl ester analysis by gas chromatography with the rapid bioterrorism database (MIDI Sherlock, Newark, NJ, USA). PCR amplifi cation, using primers that specifi cally detect the type III secretion system gene cluster of B. pseudomallei (2) , produced the predicted 115-bp band for our isolate and the positive control, B. pseudomallei strain 204 (3). Multilocus sequence typing, performed by using PCR amplifi cation conditions and primers as previously described (3), generated an allelic profi le (1, 1, 10, 2, 5, 2, 1) that was compared with those of strains of B. pseudomallei, B. mallei, and B. thailandensis stored in the database (http:// bpseudomallei.mlst.net). This profi le was unique among strains in the multilocus sequence typing database and therefore represents a novel sequence type (ST), ST707. An evolutionary analysis of ST707 with eBURST version 3 (http://eburst.mlst.net) suggested that it was most closely related to other strains of B. pseudomallei, including ST26 from Niger, ST82 from France, and ST7 from Vietnam (Figure) . B. pseudomallei is the causative agent of melioidosis, a severe illness usually characterized by fever, lymphadenopathy, and suppurative lesions in skin, liver, spleen or the lung. The organism is present in the soil to disease-endemic areas, and infection is thought to be acquired through breaks in the skin. The disease is endemic in many parts of Southeast Asia, with most cases being reported from Thailand (4). The infection is also a wellrecognized pathogen in the Northern Territory of Australia (5). In addition, sporadic cases have been described in Central and South America and the Pacifi c islands. By contrast, strikingly few human cases of melioidosis have previously been reported in Africa. Wall et al. reported a case in The Gambia in a patient originally from Sierra Leone (6), and Bremmelgaard et al. noted a case in a Danish patient who had probably acquired the infection in Kenya (7) . Despite the paucity of clinical cases reported from Africa, serologic surveys suggest that the organism is present in several countries, including Burkina Faso (8) and Uganda (9) . Moreover, B. pseudomallei has been isolated from the soil and from animals in several African countries (10, 11) .
Conclusions
Although we cannot be certain, the patient reported here likely acquired her infection in Nigeria, the most populous country on the African continent. To our knowledge, no documented cases of melioidosis acquired in Nigeria have been reported. Most cases imported into the United Kingdom originate in Southeast Asia and the Indian subcontinent (12) . Given the frequency of travel between the United Kingdom and Nigeria, the absence of imported cases from that country until now is striking. However, the patient's strain appears to be related to a strain that was isolated from neighboring Niger ≈40 years earlier.
Although the case we report here may represent a recent introduction of the organism into Nigeria, the disease may also be underdiagnosed because of the diffi culty of identifying the organism in a resource-limited setting.
Although melioidosis may affect healthy persons, infection is strongly associated with underlying diseases and with diabetes in particular. In a case-control study in Thailand, diabetes was associated with an adjusted odds ratio of 12.9 (13) . With the prevalence of diabetes projected to increase dramatically over the next few decades in the developing world (14) , melioidosis may become more common in countries such as Nigeria. Finally, from a clinical standpoint, the patient reported here highlights the need to consider the diagnosis of melioidosis, even in the absence of travel to traditional disease-endemic countries.
